Clinical Trials Directory

Trials / Completed

CompletedNCT05348642

Study to Evaluate the Effect of Pasteurized Akkermansia Muciniphila (pAkk) on Complaints Related to IBS

Study to Evaluate the Effect of Pasteurized Akkermansia Muciniphila (pAkk) on Complaints Related to Irritable Bowel Syndrome

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
90 (actual)
Sponsor
A-Mansia Biotech S.A. · Industry
Sex
All
Age
18 Years – 70 Years
Healthy volunteers
Not accepted

Summary

Double-blind, randomised, placebo-controlled study to evaluate the benefit of pasteurized Akkermansia muciniphila in reducing complaints related to irritable bowel syndrome. Further objectives are to evaluate the beneficial potential of pAkk on any anxiety and depression complaints, as well as its safety and tolerability.

Detailed description

Irritable bowel syndrome (IBS) is one of the most common disorders of gut-brain interaction, globally affecting about 10% of the population. Typical predominant traits are abdominal pain and abnormal bowel habits. The use of probiotics in IBS has been continuously assessed; in recent systematic reviews and meta-analyses, single or combined probiotic strains were indicated to have beneficial effects and good tolerability in the affected population. pAkk has recently been assessed as a safe novel food ingredient. Beneficial effects and very good tolerability of pAkk have been reported in individuals with metabolic disorders. The objective of the present clinical study - a double-blind, randomised, placebo-controlled, parallel group design, explorative pilot 12-week nutritional study, is to assess the potential of pAkk in IBS management. The main study objective is then to evaluate the benefit of pAkk in reducing complaints related to irritable bowel syndrome. Further objectives are to evaluate the beneficial potential of pAkk on any anxiety and depression complaints, as well as its safety and tolerability. In total, 90 participants will be enrolled and will attend 4 study visits: one on site and 3 televisits.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTpasteurized A. muciniphilapasteurized A. muciniphila - oral daily dose
DIETARY_SUPPLEMENTplaceboPlacebo = identical to verum regarding the form, size, taste, color and intake

Timeline

Start date
2022-07-21
Primary completion
2023-01-06
Completion
2023-01-06
First posted
2022-04-27
Last updated
2023-03-02

Locations

1 site across 1 country: Germany

Source: ClinicalTrials.gov record NCT05348642. Inclusion in this directory is not an endorsement.